Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Astella

    - PMLiVE

    AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer

    Around one in five breast cancer cases are HER2-positive

    - PMLiVE

    Medicus Pharma completes patient enrolment for basal cell carcinoma trial

    Interim results have shown over 60% clinical clearance in patients treated with SkinJect

    - PMLiVE

    Researchers at University of Geneva develop test platform for cancer treatments

    The new platform could speed up testing while reducing the need for animal models

    - PMLiVE

    Pfizer’s Hympavzi significantly reduces bleeds in haemophilia patients

    Over 800,000 people worldwide live with haemophilia

    - PMLiVE

    Pfizer’s PADCEV gets FDA approval for bladder cancer

    Bladder cancer affects more than 614,000 people globally each year

    - PMLiVE

    Merck and Blackstone agree on funding for cancer protein antibody

    The funding will support late-stage clinical development of the investigational antibody-drug conjugate

    - PMLiVE

    Pfizer and Metsera agree on merger after bidding war between Pfizer and Novo Nordisk

    The Pfizer bid was chosen by Metsera after a concern was raised about US antitrust laws regarding the Novo Nordisk offer

    - PMLiVE

    Ipsen to acquire ImCheck Therapeutics in a deal worth up to €1bn

    The acquisition includes a clinical stage acute myeloid leukaemia treatment currently in phase 1/2 trials

    - PMLiVE

    Pfizer’s Lorviqua recommended by NICE for lung cancer

    Lung cancer is the leading cause of cancer-related deaths worldwide

    - PMLiVE

    Eli Lilly’s Inluriyo approved by FDA for breast cancer

    The oral drug can be used to treat advanced or metastatic breast cancer

    - PMLiVE

    Pfizer agrees pricing and distribution deal with US government

    The agreement enables US patients to access medicines at a discount, in addition to providing Pfizer with relief from US tariffs

    - PMLiVE

    Lilly’s early Alzheimer’s disease treatment approved in the EU

    Marketing authorisation follows positive late-stage trial results

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links